Condition
AMN
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed2
Terminated2
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05394064Phase 1TerminatedPrimary
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
NCT02699190Completed
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT05008874TerminatedPrimary
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
NCT03047369Recruiting
The Myelin Disorders Biorepository Project
NCT02961803Phase 2Completed
MD1003-AMN MD1003 in Adrenomyeloneuropathy
Showing all 5 trials